<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336648">
  <stage>Registered</stage>
  <submitdate>15/03/2011</submitdate>
  <approvaldate>21/03/2011</approvaldate>
  <actrnumber>ACTRN12611000297921</actrnumber>
  <trial_identification>
    <studytitle>A Randomized controlled trial comparing Topical use of Mupirocin versus Medihoney for the prevention of infection at Tenckhoff Exit Site in Peritoneal Dialysis Patients</studytitle>
    <scientifictitle>A Randomized controlled trial comparing Topical use of Mupirocin versus Medihoney for the prevention of infection at Tenckhoff Exit Site in Peritoneal Dialysis Patients</scientifictitle>
    <utrn>N/A</utrn>
    <trialacronym>TUMMIE Trial</trialacronym>
    <secondaryid>NIl</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peritineal Dialysis patients</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Once daly application of Topical Medihoney (gauze pad) approximately10 mg ( size of a pea) at Peritoneal dialysis catheter exit site once daily (the medihoney dressing will be changed daily ) compared  topical application of small amount Mupirocin using cotton bud to Peritoneal dialysis catheter exit site once daily ( 12 months )</interventions>
    <comparator>Medihoney (Intervention ) vs Mupirocin ( control)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>time to first episode of exit site infection,peritonitis or tunnel infection -whichever comes first ( clinical assessment and microbiolgy to confirm the infection)</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Endpoints :  whether intervention results in: 
a longer time to first exit site infection ( clinical assessment / microbiology)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>whether intervention results in a longer time first episode of peritonitis (clinical assessment / microbiology)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>a longer time to infection-associated catheter removal
lower catheter-associated infection rates;
Meausred by number of catheter removal due to infection</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>a lower incidence of adverse reactions ( all adverse events will be recorded and compared between the 2 groups).
Methods used will be questionarre and occurence of resistance ( Microbiology test)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.  Patients on peritoneal dialysis.( Incident and prevalent)
2.  Able to give informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.  PD patients who had exit site infection, peritonitis, or tunnel infection within the last 4 weeks
2.  Known hypersensitivity to, or intolerance of, honey or mupirocin.
3.  On long term antibiotics for any reason.
4. Patients with a history of psychological illness or condition which interferes with their ability to understand or comply with the requirements of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation</concealment>
    <sequence>Randomisation of patients into the two groups will be based on computer generated numbers</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Safety and efficay of Medihoney vs Mupirocin</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>380</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of Renal Medicine</primarysponsorname>
    <primarysponsoraddress>Royal brisbane &amp; Women's Hospitals
Butterfield Street,
Herston, Qld, 4029</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of Renal Medicine</fundingname>
      <fundingaddress>Royal brisbane &amp; Women's Hospitals
Butterfield Street, 
Herston, Qld, 4029</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Comvita NewZealand Limited</fundingname>
      <fundingaddress>Private Bag 1, Te Puke
Phone : 64 -0800 504 959 ( No post code)</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Comvita NewZealand Limited</sponsorname>
      <sponsoraddress>Private Bag 1, Te Puke
Phone : 64 -0800 504 959 ( No post code</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>not recruiting</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Reseearch and ethics Committee</ethicname>
      <ethicaddress>Royal Brisbane &amp;Woen's hospitals
Herston, Qld, 4029</ethicaddress>
      <ethicapprovaldate>24/01/2011</ethicapprovaldate>
      <hrec>HREC/10/QRBW?422</hrec>
      <ethicsubmitdate>26/10/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dwarakanathan Ranganathan</name>
      <address>Department of Renal Medicine,
Butterfield Street, 
Royal Brisbane &amp; women's Hospitals
Herston, Qld, 4029</address>
      <phone>61-7-36368576</phone>
      <fax>61-7-36368572</fax>
      <email>dwarakanathan_ranganathan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dwarakanathan Ranganathan</name>
      <address>Department of Renal Medicine,
Butterfield Street, 
Royal Brisbane &amp; women's Hospitals
Herston, Qld, 4029</address>
      <phone>61-7-36368576</phone>
      <fax>61-7-36368572</fax>
      <email>dwarakanathan_ranganathan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dwarakanathan Ranganathan</name>
      <address>Department of Renal Medicine,
Butterfield Street, 
Royal Brisbane &amp; women's Hospitals
Herston, Qld, 4029</address>
      <phone>61-7-36368576</phone>
      <fax>61-7-36368572</fax>
      <email>dwarakanathan_ranganathan@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>